GO:0061751 neutral sphingomyelin phosphodiesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061751 describes the molecular function of neutral sphingomyelin phosphodiesterase (neutral SMase), which hydrolyzes sphingomyelin to ceramide, choline phosphate, and H+ at neutral pH.
• The reaction is a key source of ceramide, a bioactive lipid that regulates membrane structure, stress signaling, and cell fate.
• Neutral SMase activity is distinct from acid and secretory sphingomyelinases in pH optimum, subcellular localization, and regulation.
• Dysregulated neutral SMase activity is linked to cardiometabolic disease, insulin resistance, and thrombosis.
• The enzyme is regulated by membrane lipids, redox state, and protein-protein interactions, and can be modulated by anti-ganglioside antibodies.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of neutral SMase function in health and disease.
Description
Neutral sphingomyelin phosphodiesterase activity (GO:0061751) is a molecular function defined as the catalysis of the reaction H2O + sphingomyelin = ceramide + choline phosphate + H+ in a neutral environment. This activity is carried out by neutral sphingomyelinases (neutral SMases), enzymes that cleave sphingomyelin, a major membrane sphingolipid, to generate ceramide, a central lipid second messenger. Unlike acid sphingomyelinase, which functions in lysosomes, neutral SMase operates at neutral pH and is associated with membranes, including the plasma membrane and intracellular organelles. The reaction is fundamental to sphingolipid metabolism and membrane dynamics, and it influences diverse cellular processes such as proliferation, differentiation, apoptosis, and stress responses. Researchers study GO:0061751 because ceramide produced by neutral SMase is implicated in the pathogenesis of cardiometabolic diseases, including obesity, insulin resistance, and atherosclerosis. For example, neutral sphingomyelinase-2 (nSMase2) has been linked to cardiometabolic disease progression, and exercise training alters skeletal muscle sphingomyelinase activity in type 2 diabetes. Moreover, alterations in sphingomyelin metabolism affect hemostasis and thrombosis, highlighting the broader physiological impact of this activity. Understanding the molecular mechanism, regulation, and disease relevance of neutral SMase is therefore critical for developing targeted therapies and diagnostic markers. This article provides a comprehensive overview of GO:0061751, covering its definition, biological context, key genes, regulatory mechanisms, disease associations, and experimental approaches, including CRISPR-based models. All statements are grounded in published literature to support researchers in designing robust studies on this important enzyme activity.
neutral sphingomyelin phosphodiesterase activity At A Glance
| GO ID | GO:0061751 |
|---|---|
| GO term | neutral sphingomyelin phosphodiesterase activity |
| Ontology | molecular_function |
| Synonym | neutral SMase, neutral sphingomyelinase |
| Definition | Catalysis of the reaction: H2O + sphingomyelin = ceramide + choline phosphate + H+ in a neutral environment. |
| Major function | Hydrolysis of sphingomyelin to ceramide and choline phosphate at neutral pH |
| Reaction direction | Forward: sphingomyelin + H2O -> ceramide + choline phosphate + H+ |
| Cellular location | Membrane-associated (plasma membrane, Golgi, mitochondria-associated membranes) |
| pH optimum | Neutral (around pH 7.0-7.5) |
| Key regulators | Membrane lipids, redox state, protein interactions, anti-ganglioside antibodies |
What Is GO:0061751?
GO:0061751, neutral sphingomyelin phosphodiesterase activity, is defined as the catalysis of the reaction: H2O + sphingomyelin = ceramide + choline phosphate + H+ in a neutral environment. In other words, it is the enzymatic activity that breaks down sphingomyelin into ceramide and choline phosphate at neutral pH, releasing a proton. This activity is synonymous with neutral SMase and is distinct from acid sphingomyelinase (which works at acidic pH) and secretory sphingomyelinase.
Why Is neutral sphingomyelin phosphodiesterase activity Important in Cell Biology?
Neutral sphingomyelin phosphodiesterase activity (GO:0061751) is critically important because it generates ceramide, a bioactive sphingolipid that controls cell fate, inflammation, and metabolism. Ceramide produced by neutral SMase influences membrane fluidity, receptor signaling, and stress responses, and its dysregulation is implicated in cardiometabolic diseases, insulin resistance, and thrombosis. The enzyme also modulates membrane-associated sphingomyelin metabolism in response to anti-ganglioside antibodies, linking it to neuroimmunological processes. Thus, understanding GO:0061751 provides insights into fundamental lipid signaling and offers potential therapeutic targets for metabolic and cardiovascular disorders.
• Generates ceramide, a key lipid second messenger in apoptosis, senescence, and inflammation.
• Regulates membrane sphingomyelin content and membrane microdomain organization.
• Implicated in cardiometabolic diseases, including obesity, insulin resistance, and atherosclerosis.
• Altered in skeletal muscle of type 2 diabetes patients and responsive to exercise training.
• Modulates hemostasis and thrombosis through sphingomyelin metabolism.
• Targeted by anti-GM1 ganglioside antibodies, affecting membrane sphingomyelin metabolism.
• Distinct from acid and secretory sphingomyelinases, with unique pH optimum and regulation.
• Potential therapeutic target for metabolic and cardiovascular disorders.
• Serves as a biomarker for sphingolipid-related pathologies.
• Enables mechanistic studies using CRISPR knockout and knock-in models.
Molecular Mechanism of neutral sphingomyelin phosphodiesterase activity
Substrate recognition and binding
In simple terms: The enzyme grabs sphingomyelin from the membrane.
Neutral sphingomyelinase binds sphingomyelin, a sphingolipid embedded in the lipid bilayer, through a hydrophobic channel or surface patch that accommodates the ceramide backbone and phosphorylcholine headgroup. Structural studies of Bacillus cereus neutral sphingomyelinase reveal a conserved fold with a catalytic pocket that positions the substrate for hydrolysis. The enzyme preferentially acts on sphingomyelin present in membranes, and its activity is influenced by membrane lipid composition and fluidity.
Catalytic hydrolysis
In simple terms: Water splits sphingomyelin into ceramide and choline phosphate.
The catalytic mechanism involves a water molecule activated by a general base, which attacks the phosphodiester bond of sphingomyelin, yielding ceramide and choline phosphate. This reaction is pH-dependent, with optimal activity at neutral pH, and releases a proton. The enzyme requires divalent cations such as Mg2+ or Mn2+ for full activity in some isoforms, although the exact cofactor requirements vary among neutral SMases.
Product release and membrane dynamics
In simple terms: The products are released and can signal or be further metabolized.
Following hydrolysis, ceramide is released into the membrane, where it can alter membrane curvature, form ceramide-enriched platforms, and recruit signaling proteins. Choline phosphate is a water-soluble metabolite that can be recycled into phosphatidylcholine synthesis. The generation of ceramide at the membrane is a key step in stress-induced signaling and membrane remodeling.
Regulation by lipids and proteins
In simple terms: Other molecules can turn the enzyme on or off.
Neutral sphingomyelinase activity is regulated by membrane lipids such as phosphatidylserine and cholesterol, and by redox state through cysteine modifications. Protein-protein interactions, including with adaptor proteins and kinases, can modulate its localization and activity. Additionally, anti-GM1 ganglioside antibodies can alter membrane-associated sphingomyelin metabolism by affecting neutral sphingomyelinase activity.
Isoform diversity and cellular roles
In simple terms: Different versions of the enzyme exist in different parts of the cell.
Mammalian neutral sphingomyelinases include nSMase1, nSMase2, and nSMase3, which differ in tissue distribution, subcellular localization, and regulation. nSMase2 is the best-characterized isoform and is implicated in cardiometabolic diseases, while nSMase1 may have broader substrate specificity. These isoforms contribute to distinct ceramide pools and downstream signaling pathways.
Key Genes Involved in GO:0061751 neutral sphingomyelin phosphodiesterase activity
The following genes and proteins are directly or indirectly associated with neutral sphingomyelin phosphodiesterase activity (GO:0061751) based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMPD2 | Encodes neutral sphingomyelinase 1 (nSMase1) | Studied for its role in sphingomyelin hydrolysis and ceramide generation |
| SMPD3 | Encodes neutral sphingomyelinase 2 (nSMase2) | Linked to cardiometabolic diseases and insulin resistance |
| SMPD4 | Encodes neutral sphingomyelinase 3 (nSMase3) | Potential role in ER stress and membrane trafficking |
| SMPD1 | Encodes acid sphingomyelinase | Distinct from neutral SMase but shares substrate; used for comparative studies |
| SMPD5 | Encodes a putative neutral sphingomyelinase | Understudied; may contribute to neutral SMase activity |
| GM1 | Ganglioside GM1 | Anti-GM1 antibodies modulate neutral SMase activity |
| TNF | Tumor necrosis factor | Can activate neutral SMase and ceramide production |
| IL-1B | Interleukin-1 beta | Inflammatory cytokine that may influence neutral SMase |
| FAS | Fas receptor | Apoptotic signaling linked to neutral SMase activation |
| CASP3 | Caspase-3 | Effector caspase in ceramide-mediated apoptosis |
| AKT1 | Protein kinase B | Survival signaling cross-talk with ceramide |
| MAPK1 | Mitogen-activated protein kinase 1 | Stress signaling downstream of ceramide |
| PP2A | Protein phosphatase 2A | Ceramide-activated phosphatase |
| PKC | Protein kinase C | Regulated by ceramide and diacylglycerol |
| S1P | Sphingosine-1-phosphate | Product of ceramide metabolism, opposing signaling |
| CERK | Ceramide kinase | Converts ceramide to ceramide-1-phosphate |
| ASAH1 | Acid ceramidase | Degrades ceramide to sphingosine |
| SGMS1 | Sphingomyelin synthase 1 | Generates sphingomyelin, opposing neutral SMase |
How Is neutral sphingomyelin phosphodiesterase activity Regulated?
Neutral sphingomyelin phosphodiesterase activity is regulated at multiple levels. Membrane lipid composition, particularly cholesterol and phosphatidylserine, modulates enzyme activity and substrate accessibility. Redox state can influence activity through cysteine oxidation, and various cytokines such as TNF and IL-1β can stimulate neutral SMase. Protein-protein interactions and phosphorylation events also contribute to regulation. In skeletal muscle, exercise training increases sphingomyelinase activity in men with type 2 diabetes, indicating physiological regulation. Additionally, anti-GM1 ganglioside antibodies can alter membrane-associated sphingomyelin metabolism by modulating neutral sphingomyelinase activity.
neutral sphingomyelin phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMPD3 | Cardiometabolic diseases, insulin resistance | Knockout mouse, overexpression in adipocytes |
| SMPD2 | Sphingolipid metabolism disorders | CRISPR knockout in cell lines |
| SMPD1 | Niemann-Pick disease (acid SMase deficiency) | Point mutation knock-in |
| GM1 | Guillain-Barré syndrome, neuropathies | Anti-GM1 antibody treatment in neuronal cultures |
| SMPD3 | Thrombosis and hemostasis | Platelet-specific knockout |
Cardiometabolic diseases
Neutral sphingomyelinase-2 (nSMase2) and ceramide generated by neutral SMase are implicated in obesity, insulin resistance, and atherosclerosis. Elevated ceramide levels contribute to impaired insulin signaling and endothelial dysfunction, making neutral SMase a potential therapeutic target. Exercise training can modulate sphingomyelinase activity in skeletal muscle of type 2 diabetes patients, suggesting a link between physical activity and sphingolipid metabolism.
Thrombosis and hemostasis
Alterations in sphingomyelin metabolism affect hemostasis and thrombosis. Neutral SMase activity influences platelet function and coagulation pathways, and dysregulation may contribute to thrombotic disorders. This highlights the importance of sphingolipid balance in vascular biology.
Neuroimmunological disorders
Anti-GM1 ganglioside antibodies, which are associated with Guillain-Barré syndrome and other neuropathies, can modulate membrane-associated sphingomyelin metabolism by altering neutral sphingomyelinase activity. This suggests a role for neutral SMase in neuroinflammatory and autoimmune conditions.
From neutral sphingomyelin phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of neutral SMase reduce ceramide and affect insulin signaling? | SMPD3 knockout cell line or mouse |
| What is the effect of a specific point mutation on catalytic activity? | CRISPR point-mutation knock-in of SMPD3 |
| How does tagged neutral SMase localize in live cells? | Knock-in of fluorescent tag (e.g., GFP) at SMPD3 locus |
| Does overexpression of neutral SMase increase ceramide and apoptosis? | Overexpression of SMPD2 or SMPD3 in cell lines |
| What genes modulate neutral SMase activity in a genome-wide screen? | CRISPR library screening |
| How does exercise affect skeletal muscle sphingomyelinase? | Human skeletal muscle biopsies and cell models |
How to Study the neutral sphingomyelin phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioenzymatic assay | Neutral SMase activity | Kinetic studies and inhibitor testing |
| Fluorescent substrate assay | Enzyme activity in real time | High-throughput screening |
| Lipidomics (LC-MS) | Sphingomyelin and ceramide levels | Disease biomarker discovery |
| CRISPR knockout screen | Genes affecting neutral SMase activity | Novel regulator identification |
| Western blot | Protein expression of SMPD isoforms | Validation of knockout or overexpression |
| Immunofluorescence | Subcellular localization | Membrane trafficking studies |
| qPCR | mRNA levels of SMPD genes | Gene expression analysis |
| Ceramide ELISA | Ceramide quantification | Clinical sample analysis |
Enzymatic activity assays
Neutral sphingomyelinase activity is typically measured using radiolabeled or fluorescent sphingomyelin substrates in neutral pH buffers, followed by quantification of ceramide or choline phosphate products. These assays are essential for validating enzyme kinetics and inhibitor effects.
Lipidomics and mass spectrometry
Mass spectrometry-based lipidomics enables comprehensive profiling of sphingomyelin and ceramide species in cells and tissues, providing insights into neutral SMase function in physiological and pathological states. This approach can quantify changes in sphingolipid pools following genetic or pharmacological manipulation.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate neutral SMase activity or ceramide levels. Such screens are powerful for discovering novel regulators and pathways linked to GO:0061751.
Imaging and subcellular localization
Fluorescence microscopy with tagged neutral SMase or ceramide-specific probes can reveal subcellular localization and dynamics of the enzyme and its product. Live-cell imaging helps track membrane remodeling and ceramide platform formation.
How CRISPR Can Be Used to Study GO:0061751 neutral sphingomyelin phosphodiesterase activity
Knockout
CRISPR knockout of SMPD2, SMPD3, or SMPD4 eliminates neutral sphingomyelinase activity, enabling studies of ceramide depletion on cell signaling, metabolism, and disease phenotypes. Knockout cell lines are valuable for validating specific isoform contributions to GO:0061751.
Point Mutation
CRISPR point mutation can introduce catalytic-dead mutations or disease-associated variants into SMPD genes to dissect enzymatic activity from scaffolding functions. Such models help define the precise residues required for sphingomyelin hydrolysis.
Knock-in
Knock-in of epitope tags, fluorescent proteins, or conditional alleles at the endogenous SMPD locus allows real-time tracking of neutral SMase expression and localization without overexpression artifacts. This approach is ideal for studying endogenous regulation.
Overexpression
CRISPR activation or cDNA overexpression of SMPD3 increases neutral SMase activity and ceramide production, useful for gain-of-function studies on apoptosis, insulin resistance, and thrombosis. Overexpression models can reveal downstream effects of elevated ceramide.
How EDITGENE Supports neutral sphingomyelin phosphodiesterase activity Research
Researchers studying neutral sphingomyelin phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in ceramide production, metabolic dysfunction, or thrombosis. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of GO:0061751-associated genes.
Contact EDITGENE today to design your custom CRISPR model for neutral sphingomyelin phosphodiesterase activity research.
Frequently Asked Questions About neutral sphingomyelin phosphodiesterase activity
What is neutral sphingomyelin phosphodiesterase activity?
It is the enzymatic activity (GO:0061751) that hydrolyzes sphingomyelin to ceramide and choline phosphate at neutral pH.
What genes are involved in neutral sphingomyelin phosphodiesterase activity?
Key genes include SMPD2, SMPD3, and SMPD4, which encode neutral sphingomyelinase isoforms.
What is the difference between neutral and acid sphingomyelinase?
Neutral sphingomyelinase works at neutral pH and is membrane-associated, while acid sphingomyelinase functions in lysosomes at acidic pH.
How is neutral sphingomyelinase activity measured?
It is commonly measured using radiolabeled or fluorescent sphingomyelin substrates in neutral pH buffers, followed by product detection.
What diseases are linked to neutral sphingomyelinase?
It is linked to cardiometabolic diseases, insulin resistance, thrombosis, and neuroimmunological disorders.
Can CRISPR be used to study neutral sphingomyelinase?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect its function.
What is the role of ceramide produced by neutral SMase?
Ceramide acts as a lipid second messenger in apoptosis, stress responses, and membrane remodeling.
How does exercise affect neutral sphingomyelinase?
Exercise training increases skeletal muscle sphingomyelinase activity in men with type 2 diabetes.
What are the isoforms of neutral sphingomyelinase?
Mammalian isoforms include nSMase1 (SMPD2), nSMase2 (SMPD3), and nSMase3 (SMPD4).
What is the reaction catalyzed by neutral sphingomyelin phosphodiesterase?
H2O + sphingomyelin = ceramide + choline phosphate + H+ in a neutral environment.
Conclusion
Neutral sphingomyelin phosphodiesterase activity (GO:0061751) is a fundamental enzymatic function that generates ceramide, a critical lipid mediator in cell signaling and metabolism. Its dysregulation is implicated in cardiometabolic diseases, thrombosis, and neuroimmunological conditions, making it a compelling target for therapeutic intervention. Advances in CRISPR-based models and lipidomics are accelerating our understanding of this activity and its regulatory networks. Continued research into GO:0061751 will likely uncover new diagnostic and therapeutic opportunities for sphingolipid-related disorders.
References
- 1. Sindhu S et al.. 2021. Neutral sphingomyelinase-2 and cardiometabolic diseases.. Obes Rev 22(8):e13248 PMID: 33738905
- 2. Ago H et al.. 2006. Structural basis of the sphingomyelin phosphodiesterase activity in neutral sphingomyelinase from Bacillus cereus.. J Biol Chem 281(23):16157-67 PMID: 16595670
- 3. Ueda A et al.. 2018. Anti-GM1 ganglioside antibodies modulate membrane-associated sphingomyelin metabolism by altering neutral sphingomyelinase activity.. Mol Cell Neurosci 89:42-48 PMID: 29601870
- 4. Chatterjee S. 1993. Neutral sphingomyelinase.. Adv Lipid Res 26:25-48 PMID: 8379453
- 5. Hendlinger M et al.. 2025. Exercise training increases skeletal muscle sphingomyelinases and affects mitochondrial quality control in men with type 2 diabetes.. Metabolism 172:156361 PMID: 40759392
- 6. Tabas I. 1999. Secretory sphingomyelinase.. Chem Phys Lipids 102(1-2):123-30 PMID: 11001566
- 7. Goñi FM et al.. 2002. Sphingomyelinases: enzymology and membrane activity.. FEBS Lett 531(1):38-46 PMID: 12401200
- 8. Wang J et al.. 2023. Alterations to Sphingomyelin Metabolism Affect Hemostasis and Thrombosis.. Arterioscler Thromb Vasc Biol 43(1):64-78 PMID: 36412194
